O albinismo oculocutâneo tipo 1A (OCA1A) é a forma mais grave de albinismo, pois não há produção de melanina. Ele é caracterizado por cabelos e pele brancos, íris azuis totalmente translúcidas, nistagmo (movimentos involuntários dos olhos) e um desvio no caminho dos nervos ópticos.
Introdução
O que você precisa saber de cara
O albinismo oculocutâneo tipo 1A (OCA1A) é a forma mais grave de albinismo, pois não há produção de melanina. Ele é caracterizado por cabelos e pele brancos, íris azuis totalmente translúcidas, nistagmo (movimentos involuntários dos olhos) e um desvio no caminho dos nervos ópticos.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 12 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 31 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.
This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine (By similarity). In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone (PubMed:28661582)
Melanosome membraneMelanosome
Albinism, oculocutaneous, 1A
An autosomal recessive disorder in which the biosynthesis of melanin pigment is absent in skin, hair, and eyes. It is characterized by complete lack of tyrosinase activity due to production of an inactive enzyme. Patients present with a life-long absence of melanin pigment after birth, and manifest increased sensitivity to ultraviolet radiation with predisposition to skin cancer. Visual anomalies include decreased acuity, nystagmus, strabismus and photophobia.
Variantes genéticas (ClinVar)
408 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 221 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
2 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Albinismo oculocutâneo tipo 1A
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
Publicações mais relevantes
Aggressive Amelanotic Melanoma in a Patient with Oculocutaneous Albinism Type 1A: A Case with Limited Response to Targeted and Immunotherapy.
TYROSINASE-Deficient Human Retinal Pigment Epithelium Exhibits Melanosome Maturation Defects.
Oculocutaneous albinism type 1A (OCA1A) is a rare recessive genetic condition caused by mutations in TYROSINASE (TYR) that results in pigmentation defects of the skin, hair and eyes. This study was performed to understand melanosome biogenesis and maturation defects in an OCA1A in vitro model using retinal pigment epithelium (RPE) derived from TYR knockout human induced pluripotent stem cells (iPSC). CRISPR-Cas9 was used to knockout the TYR gene in iPSC to generate an isogenic pair. A developmentally guided protocol was used to differentiate the isogenic iPSC pair towards RPE monolayer tissue. Monolayer organization, melanosome formation and maturation were studied using electron microscopy. Loss of TYR protein was studied using Western blot and immuno-fluorescence staining. RPE cellular morphology and junction integrity was studied using immunofluorescence staining and transepithelial resistance measurements. An isogenic pair comprising of untargeted control and TYR knockout iPSC were successfully differentiated towards RPE monolayer tissue with polygonal cell morphology. TYR knockout RPE exhibited significantly reduced TYR protein, increased presence of immature pre-melanosomes and a complete lack of mature melanosomes. We observed abnormal junctional localization of β-catenin staining pattern, as has been reported previously for albino mouse RPE- and OCA1A patient-derived RPE. Differentiation of TYR-deficient iPSC toward RPE displayed pigmentation defects and absence of mature melanosomes, whereas melanosome biogenesis was not affected, because pre-melanosomes were still observed. These observations were also similar to what was observed in OCA1A patient-derived RPE monolayer tissue, independently confirming the validity of these previous findings.
Genetic Diagnosis of Oculocutaneous Albinism Type 1A: A Novel TYR Variant.
Oculocutaneous albinism type IA (OCA1A) is a rare autosomal recessive disorder caused by variants in the TYR gene, resulting in complete loss of tyrosinase activity and absence of melanin production. In this study, we report a novel missense variant, TYR (NM_000372.5):c.143A>C (p.Gln48Pro), found within exon 1 and mapped to chr11: g.89178096A>C (GRCh38/hg38). This variant was identified through exome sequencing in a 4-year-old Iranian girl from a consanguineous family presenting with features of OCA1A. This discovery expands the mutational spectrum of OCA1 and underscores the importance of genetic screening in diagnosing rare inherited disorders. Future studies involving functional assays are necessary to elucidate the molecular mechanisms of this variant and its potential impact on melanogenesis.
Does Early Glasses Wear Improve Visual Outcome in OCA1A?
Purpose: Oculocutaneous albinism type 1A (OCA1A), with lifelong absent melanin in skin, hair, and eyes, is the most severe type of albinism with greatest ametropia and poorest vision. We evaluated the relationship between age when spectacles were begun and visual outcome, in addition to status of refraction, in OCA1A. Methods: After IRB approval, a retrospective review of 70 consecutive charts of patients with OCA1A identified 24 fitting inclusion criterion of BCVA recorded at age 10-12 years. Exclusion criteria were those with other vision-threatening diagnoses and patients seen for a single visit. We recorded sex, age at beginning glasses, and refraction and BCVA at age 10-12 and most recent visit. Data were arbitrarily grouped by those initiating glasses at ≤ age 12 months and > age 12 months. Results: Regression analysis showed a larger degree of astigmatism was weakly associated with worse vision at age 10-12 years. A weakly positive relationship was found between poorer BCVA at last visit and older age at which glasses were initiated. All receiving glasses by age 1 and only half receiving glasses when older had improved visual acuity from age 10-12 years to last follow up. Conclusion: Additional study of a larger sample of this rare disorder is needed to determine if early glasses wear improves later BCVA.
Modeling human point mutation diseases in Xenopus tropicalis with a modified CRISPR/Cas9 system.
Precise single-base editing in Xenopus tropicalis would greatly expand the utility of this true diploid frog for modeling human genetic diseases caused by point mutations. Here, we report the efficient conversion of C-to-T or G-to-A in X. tropicalis using the rat apolipoprotein B mRNA editing enzyme catalytic subunit 1-XTEN-clustered regularly interspaced short palindromic repeat-associated protein 9 (Cas9) nickase-uracil DNA glycosylase inhibitor-nuclear localization sequence base editor [base editor 3 (BE3)]. Coinjection of guide RNA and the Cas9 mutant complex mRNA into 1-cell stage X. tropicalis embryos caused precise C-to-T or G-to-A substitution in 14 out of 19 tested sites with efficiencies of 5-75%, which allowed for easy establishment of stable lines. Targeting the conserved T-box 5 R237 and Tyr C28 residues in X. tropicalis with the BE3 system mimicked human Holt-Oram syndrome and oculocutaneous albinism type 1A, respectively. Our data indicate that BE3 is an easy and efficient tool for precise base editing in X. tropicalis.-Shi, Z., Xin, H., Tian, D., Lian, J., Wang, J., Liu, G., Ran, R., Shi, S., Zhang, Z., Shi, Y., Deng, Y., Hou, C., Chen, Y. Modeling human point mutation diseases in Xenopus tropicalis with a modified CRISPR/Cas9 system.
Publicações recentes
Aggressive Amelanotic Melanoma in a Patient with Oculocutaneous Albinism Type 1A: A Case with Limited Response to Targeted and Immunotherapy.
TYROSINASE-Deficient Human Retinal Pigment Epithelium Exhibits Melanosome Maturation Defects.
Genetic Diagnosis of Oculocutaneous Albinism Type 1A: A Novel TYR Variant.
Does Early Glasses Wear Improve Visual Outcome in OCA1A?
Modeling human point mutation diseases in Xenopus tropicalis with a modified CRISPR/Cas9 system.
📚 EuropePMC618 artigos no totalmostrando 6
Aggressive Amelanotic Melanoma in a Patient with Oculocutaneous Albinism Type 1A: A Case with Limited Response to Targeted and Immunotherapy.
Clinical and experimental dermatologyTYROSINASE-Deficient Human Retinal Pigment Epithelium Exhibits Melanosome Maturation Defects.
Investigative ophthalmology & visual scienceGenetic Diagnosis of Oculocutaneous Albinism Type 1A: A Novel TYR Variant.
Clinical case reportsDoes Early Glasses Wear Improve Visual Outcome in OCA1A?
Journal of binocular vision and ocular motilityModeling human point mutation diseases in Xenopus tropicalis with a modified CRISPR/Cas9 system.
FASEB journal : official publication of the Federation of American Societies for Experimental BiologyThe Molecular Basis of Chemical Chaperone Therapy for Oculocutaneous Albinism Type 1A.
The Journal of investigative dermatologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Albinismo oculocutâneo tipo 1A.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Albinismo oculocutâneo tipo 1A
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Aggressive Amelanotic Melanoma in a Patient with Oculocutaneous Albinism Type 1A: A Case with Limited Response to Targeted and Immunotherapy.
- TYROSINASE-Deficient Human Retinal Pigment Epithelium Exhibits Melanosome Maturation Defects.
- Genetic Diagnosis of Oculocutaneous Albinism Type 1A: A Novel TYR Variant.
- Does Early Glasses Wear Improve Visual Outcome in OCA1A?
- Modeling human point mutation diseases in Xenopus tropicalis with a modified CRISPR/Cas9 system.FASEB journal : official publication of the Federation of American Societies for Experimental Biology· 2019· PMID 30844313mais citado
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:79431(Orphanet)
- OMIM OMIM:203100(OMIM)
- MONDO:0008745(MONDO)
- GARD:16721(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q50349668(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar